Core Viewpoint - The proposed transfer of shares from China Baoyuan Investment Co., Ltd. to China National Nuclear Corporation (CNNC) will enhance CNNC's direct control over China Tongfu (01763) and strengthen its position in the nuclear technology application industry [1][2]. Group 1: Share Transfer Details - China Baoyuan intends to transfer all of its 108 million domestic shares, representing approximately 33.79% of the total issued share capital, to CNNC [1]. - After the proposed transfer, CNNC will directly hold 108 million domestic shares (approximately 33.79% of the total issued share capital) and indirectly hold an additional 128 million domestic shares through various subsidiaries, totaling 236 million domestic shares, which is about 73.83% of the total issued share capital [1]. Group 2: Implications for the Company - Following the proposed transfer, China Baoyuan will no longer be a shareholder, while CNNC will remain the ultimate controlling shareholder of the company [2]. - CNNC's brand influence and industry background are expected to significantly enhance the company's position in technological innovation and market expansion, contributing to high-quality development [2]. - The company is anticipated to play a more critical role and assume greater responsibilities with the support of CNNC, thereby increasing its impact and core competitiveness in the industry [2].

Group 1 - The proposed transfer involves the transfer of 108 million domestic shares (approximately 33.79% of the total issued share capital) from China Baoyuan Investment Co., Ltd. to China National Nuclear Corporation (CNNC) [1][2] - After the proposed transfer, CNNC will directly hold 108 million domestic shares (approximately 33.79% of the total issued share capital) and indirectly hold an additional 128 million domestic shares (approximately 40.04% of the total issued share capital) through various subsidiaries, totaling 236 million domestic shares (approximately 73.83% of the total issued share capital) [1][2] Group 2 - Following the proposed transfer, China Baoyuan will no longer be a shareholder of the company, while CNNC will remain the ultimate controlling shareholder [2] - CNNC is positioned as a national leader in nuclear technology application, which is expected to enhance the company's status, influence, and core competitiveness in technology innovation and market expansion [2]

Core Viewpoint - China Tongfu (01763.HK) announced a proposed transfer of 108,085,353 domestic shares (approximately 33.79% of the total issued share capital) from its controlling shareholder, China Baoyuan Investment Co., Ltd., to its ultimate controlling shareholder, China National Nuclear Corporation (CNNC) [1] Group 1 - After the proposed transfer, CNNC will directly hold 108,085,353 domestic shares (approximately 33.79% of the total issued share capital) and will indirectly hold an additional 128,064,880 domestic shares through its subsidiaries, totaling 236,150,233 domestic shares, which represents approximately 73.83% of the total issued share capital post-transfer [1] - CNNC is recognized as a national leader in nuclear technology applications, and its brand influence and industry background are expected to significantly enhance the company's position, influence, and core competitiveness in technology innovation and market expansion [1] - The support from CNNC will enable the company to play a more critical role, undertake more significant responsibilities, and have a more pronounced impact in the industry [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 截至本公告日期，中核集團並未直接持有本公司股份，而是通過中國寶原、中 國原子能科學研究院（「原子能院」）、中國核動力研究設計院（「核動力院」）、北 京中核產業投資基金（有限合夥）（「中核基金」）及中核四〇四有限公司（「四〇四 公司」）間接持有本公司236,150,233股內資股，約佔本公司截至本公告日期全部 已發行股本總額的73.83%。擬議無償劃轉完成後，中核集團將直接持有本公司 108,085,353股內資股（約佔擬議無償劃轉完成後本公司全部已發行股本總額的 33.79%），並通過原子能院、核動力院、中核基金及四〇四公司間接持有本公司 128,064,880股內資股（約佔擬議無償劃轉完成後本公司全部已發行股本總額的 40.04%），即合計持有本公司236,150,233股內資股，約佔擬議無償劃轉完成後本 公司全部已發行股本總額的73.83%。 擬議無償劃轉完成後，中國寶原將不再是本公司的股東，而中核 ...

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on the distribution of radioactive drugs in the body to obtain physiological and pathological information [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear medicine imaging equipment, and radiation therapy devices [2] Development Environment - The Chinese government has been actively promoting the nuclear medicine industry through various policies, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - Local governments, such as in Guangdong and Sichuan, have also introduced plans to accelerate the development of the nuclear medicine sector [6][7] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant advancements in technology and capabilities, transitioning from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Nuclear Industry, East China Pharmaceutical, and Yuanda Medical, with East China Pharmaceutical holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new radioactive drug developments, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in diverse nuclear medicine services [20]

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on imaging and radiotherapy [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear imaging equipment, and radiotherapy devices [2] Development Environment - The Chinese government has implemented various policies to support the nuclear medicine industry, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - These policies aim to enhance innovation, expand clinical applications, and create new opportunities for related enterprises [6] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant technological advancements, moving from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Dongfang, East Cheng Pharmaceutical, and Yuanda Medical, with East Cheng holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new drug development, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in nuclear medicine services [20]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 2. 股份分類 | ...

Core Viewpoint - China Nuclear High-Tech (01763.HK) announced plans for capital increase through Beijing Property Exchange to address funding needs and optimize capital structure [1] Group 1: Company Financials - As of December 31, 2024, China Nuclear High-Tech's subsidiary, Chengdu Zhongke Gaotong Isotope Co., has a debt-to-asset ratio of 68.41% [1] - The capital increase aims to alleviate financial pressure and support core business expansion and operational capacity enhancement [1] Group 2: Strategic Implications - The board believes that the capital increase will ensure sustainable development for China Nuclear High-Tech and align with overall financial management requirements [1] - This move is expected to enhance the overall asset quality and risk resistance capability of the group [1]

中国同辐(01763)公布，公司非全资附属公司成都中核高通同位素股份有限公司(中核高通)拟透过于北京 产权交易所公开褂牌程序进行增资。 截至2024年12月31日，中核高通资产负债率为68.41%，为解决发展资金需求及优化其资本结构，中核 高通拟透过潜在增资事项缓解其资金压力，支持其核心业务拓展及运营能力提升。董事会认为，此次增 资既能保障中核高通的可持续发展，亦符合集团整体财务管控要求，有利于增强集团整体资产品质和抗 风险能力。 ...

截至2024年12月31日，中核高通资产负债率为68.41%，为解决发展资金需求及优化其资本结构，中核 高通拟透过潜在增资事项缓解其资金压力，支持其核心业务拓展及运营能力提升。董事会认为，此次增 资既能保障中核高通的可持续发展，亦符合集团整体财务管控要求，有利于增强集团整体资产品质和抗 风险能力。 智通财经APP讯，中国同辐(01763)公布，公司非全资附属公司成都中核高通同位素股份有限公司(中核 高通)拟透过于北京产权交易所公开褂牌程序进行增资。 ...